CTLA4 and cancer: Although the immune-related adverse events of anti-CTLA-4 mAb treatment are frequent and sometimes severe, anti-CLTA-4 treatment is the first proof-of-concept therapeutic strategy for checkpoint inhibition in cancer immunotherapy.